Table of Contents

company-logo

BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops valoctocogene roxaparvovec, an adeno associated virus vector, which is in Phase III clinical trial for the treatment of patients with severe hemophilia A; BMN 307, an AAV5 mediated gene therapy, which is in Phase 1/2 clinical trial to normalize blood Phe concentration levels in patients with PKU; and BMN 255 that is in Phase 1/2 clinical trial for treating primary hyperoxaluria. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has license and collaboration agreements with Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc., and Asubio Pharma Co., Ltd. The company was incorporated in 1996 and is headquartered in San Rafael, California.

BioMarin Pharmaceutical Dividend Announcement

• BioMarin Pharmaceutical does not currently offer dividends, we're keeping a close eye on its growth potential and financial developments.
• Stay tuned for updates on BioMarin Pharmaceutical dividend policy and future announcements. In the meantime, explore other dividend-yielding opportunities on our website.

BioMarin Pharmaceutical Dividend History

BioMarin Pharmaceutical Dividend Yield

BioMarin Pharmaceutical current trailing twelve-month (TTM) dividend yield is -%. Interested in purchasing BioMarin Pharmaceutical stock? Use our calculator to estimate your expected dividend yield:

BioMarin Pharmaceutical Financial Ratios

P/E ratio38.46
PEG ratio4.07
P/B ratio2.29
ROE6.22%
Payout ratio0.00%
Current ratio4.27
Quick ratio2.62
Cash Ratio0.94

BioMarin Pharmaceutical Dividend FAQ

Does BioMarin Pharmaceutical stock pay dividends?
BioMarin Pharmaceutical does not currently pay dividends to its shareholders.
Has BioMarin Pharmaceutical ever paid a dividend?
No, BioMarin Pharmaceutical has no a history of paying dividends to its shareholders. BioMarin Pharmaceutical is not known for its dividend payments.
Why doesn't BioMarin Pharmaceutical pay dividends?
There are several potential reasons why BioMarin Pharmaceutical would choose not to pay dividends to their shareholders:

1. Growth opportunities: Companies, especially in fast-growing industries like technology, reinvest earnings into expansion, R&D, or acquisitions to fuel future growth and increase company value.

2. Tax implications: Not paying dividends can reduce the tax burden on shareholders, who may prefer to defer taxes until selling shares and realizing capital gains.

3. Investor preferences: Some investors prefer companies to reinvest profits for higher long-term returns, particularly those seeking capital appreciation over income.

4. Capital allocation priorities: Companies may allocate cash to pay down debt, fund share buybacks, or invest in projects with higher returns than dividends.

5. Market expectations: In certain sectors, like technology, reinvesting profits for growth and innovation is often prioritized over distributing dividends to shareholders.
Will BioMarin Pharmaceutical ever pay a dividend?
The decision for a company to pay dividends depends on various factors including its financial performance, growth prospects, capital allocation priorities, and shareholder preferences. While BioMarin Pharmaceutical has not paid dividends historically and has instead focused on reinvesting its earnings for growth, it's ultimately up to the company's management and board of directors to decide whether to initiate a dividend policy in the future.
Is BioMarin Pharmaceutical a dividend aristocrat?
BioMarin Pharmaceutical is not considered a Dividend Aristocrat. The term "Dividend Aristocrat" is typically used to describe a company in the S&P 500 index that has increased its dividend payouts for at least 25 consecutive years.
Is BioMarin Pharmaceutical a dividend king?
BioMarin Pharmaceutical is not classified as a "Dividend King". A Dividend King is a company that has managed to increase its dividend payouts for 50 consecutive years or more, which is an even more selective group than the Dividend Aristocrats.
Is BioMarin Pharmaceutical a dividend stock?
No, BioMarin Pharmaceutical is not considered a dividend stock. A dividend stock is a stock of a company that regularly pays out dividends to its shareholders.
How to buy BioMarin Pharmaceutical stocks?
To buy BioMarin Pharmaceutical you need a brokerage account. Open an account with a reputable brokerage firm that offers access to the stock market. Consider factors such as fees and account minimums.

Place an order: Use the brokerage's trading platform to place an order to buy BioMarin Pharmaceutical stock.

Remember that buying stocks involves risk, and it's important to carefully consider your investment goals, risk tolerance, and conduct thorough research before making any investment decisions.